HANSHOW
27.3.2024 10:56:30 CET | Business Wire | Press release
From March 13th to 15th, the 24th China Retail Expo was held at Shanghai's National Convention and Exhibition Center. Under the theme "Green Digitalization and GenAI for Sustainable Retail," Hanshow debuted its pioneering GenAI product strategy, marking a significant leap forward in retail's AI era. The showcase included the upgraded Hanshow Polaris Pro series electronic shelf labels (ESL) and a new green digital store solution, reaffirming Hanshow's dedication to providing retailers with cutting-edge technologies for enhanced efficiency, improved shopper experiences, and sustainable practices.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240320389359/en/
The breakthrough of Generative Pre-trained Transformer 3 (GPT-3) technology, represented by represented by ChatGPT, has expanded the boundaries of all industries. Hanshow is Microsoft’s global strategy partner in the retail industry since 2023 and is one of the first to incorporate GenAI technology in retail scenarios using Azure OpenAI (AOAI).
At the event, Eason Tong, Dean of the Hanshow Retail Research Institute, announced Hanshow's first GenAI solution for retail business operations based on strategic cooperation with Microsoft. For retailers, Hanshow uses OpenAI's large model capabilities integrated with massive digital retail data to create the industry's first automated content (copy + image) generation intelligent application solution - the Hanshow Store Marketing Assistant.
The GenAI solution released by Hanshow relies on open source GPT-4 text output and Dall-E3 image output and can generate commodity POP posters, marketing atmosphere posters, and product copy through dialogue interaction. The internal integration of Hanshow's product ecosystem allows the generated materials to be uploaded and shown on the Hanshow Lumina Screen and upcoming large-sized colorful electronic paper posters with one click.
With the Hanshow Store Marketing Assistant, stores can easily generate a variety of creatively designed marketing materials to vividly portray product selling points while controlling marketing costs and improving sales. Whether it is a store operator or a brand owner, retailers can use the solution to reduce creative work from several hours to a few minutes.
"Hanshow is dedicated to offering retailers a retail media network solution that diversifies income streams. Leveraging generative AI for content, personalization, and impact assessment, we support future store media networks comprehensively," said Tong.
Microsoft and its ecosystem have supported Hanshow in building a digital store solution based on Azure OpenAI capabilities, and the two parties are deepening their cooperation and accelerating the landing of generative AI in global physical retail scenarios.
Microsoft and Hanshow jointly held a high-level roundtable forum to explore revolutionary omnichannel GenAI retail applications and trends and the green development and digital transformation of the retail industry.
"GenAI's remarkable capabilities are revolutionizing various industries. We're delighted to see Hanshow, Microsoft's global strategic partner, leveraging Azure OpenAI technology to introduce generative AI into physical retail. As a pioneer in retail digitalization, Hanshow combines industry insights with GenAI to present innovative digital store solutions," stated Frank Kong, Microsoft China's General Manager of Retail Consumer Goods.
Coming up, Hanshow and Microsoft’s GenAI marketing solutions for consumers will also be unveiled at the NRF exhibition in Singapore in June 2024, covering the four areas of store operations, consumer experience, store media, and green energy.
About Hanshow
Hanshow is one of the global leaders in the development and manufacturing of electronic shelf labels and digital store solutions. The company offers customers a series of customized IoT touchpoints and digital store solutions that deliver customer-centric insights. Hanshow's solutions have provided services to a vast number of stores across more than 50 countries and regions, helping them streamline operations, optimize pricing strategies, and offer consumers a more personalized experience. Learn more: www.hanshow.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240320389359/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom